Table 1.
Cardiovascular (CV) comorbidities and complications in patients with COVID-19.
| Cases | Hospital | Age | Cardiovascular comorbidity | Cardiovascular complications | Ref |
|---|---|---|---|---|---|
| 41 | Jinyintan Hospital | 49 (41–58) | CVD (15%), hypertension (15%) | Acute cardiac injury* (12%) | [7] |
| 138 | Zhongnan Hospital | 56 (42–68) | Hypertension (31.2%), CVD (14.5%), cerebrovascular (5.1%) | Acute cardiac injury (7.2%), shock (8.7%) and arrhythmia (16.7%) | [6] |
| 1099 | 552 Hospitals in China | 47 (35–58) | Hypertension (15%), CAD (2.5%), cerebrovascular (1.4%) | Creatine kinase ≥ 200 U/L (13.7%), and septic shock (1.1%) | [11] |
| 21 | Evergreen Hospital | 70 (43–92) | Congestive heart failure (42.9%), troponin level > 0.3 ng/mL (14%) | Cardiomyopathy** (33.3%) | [29] |
| 137 | 9 Tertiary Hospitals in Hubei | 57 (20–83) | Hypertension (9.5%) and CVD (7.3%) | Symptom of heart palpitation (7.3%) and comorbid organ dysfunction (18.9%) | [22] |
| 149 | 3 Tertiary Hospitals Wenzhou | 45 (32–58) | Cardio-cerebrovascular disease (18.79%) | Symptoms of Chest pain (3.36%) and chest tightness (10.74%), increased creatine kinase (8.05%) | [88] |
| 140 | No.7 Hospital of Wuhan | 57 (25–87) | Hypertension (30%), CAD (5%), hyperlipidemia (5%), arrhythmia (3.6%), stroke (2.1%), aorta sclerosis (1.4%) | Symptom of dyspnea/chest tightness (36.7%), increased creatine kinase (6.7%) | [89] |
| 80 | 3 Hospitals in Jiangsu | 46 (31–62) | CVD and cerebrovascular disease (31.25%) | Symptom of chest pain (3.75%) and increased creatine kinase-MB (20%) | [90] |
| 187 | The 7th Hospital of Wuhan | 59 (44–73) | Hypertension (32.6%), coronary heart disease (11.2%), and cardiopathy (4.3%) | Myocardial injury (27.8%), ventricular tachycardia/ fibrillation (5.9%), acute coagulopathy (34.1%) | [24] |
*Acute cardiac injury is defined as the increased of biomarkers of myocardial injury or new abnormalities in electrocardiogram and echocardiogram. **Cardiomyopathy is defined as decreased of left ventricular ejection fraction to clinical symptoms of cardiogenic shock, an increase of myocardial biomarkers, or a decrease of central venous oxygen saturation (<70%) with no past history of contraction dysfunction.